Publications
Found 1 results
Filters: Author is E.F. Rodrigues [Clear All Filters]
“Accurate monitoring of promoter gene methylation with high-resolution melting polymerase chain reaction using the ABCB1 gene as a model”, vol. 12, pp. 714-722, 2013.
, Abolhoda A, Wilson AE, Ross H, Danenberg PV, et al. (1999). Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin. Cancer Res. 5: 3352-3356.
PMid:10589744
Ando T, Nishimura M and Oka Y (2000). Decitabine (5-Aza-2'-deoxycytidine) decreased DNA methylation and expression of MDR-1 gene in K562/ADM cells. Leukemia 14: 1915-1920.
http://dx.doi.org/10.1038/sj.leu.2401914
PMid:11069027
Baker EK, Johnstone RW, Zalcberg JR and El-Osta A (2005). Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene 24: 8061-8075.
http://dx.doi.org/10.1038/sj.onc.1208955
PMid:16091741
Chen KG and Sikic BI (2012). Molecular pathways: regulation and therapeutic implications of multidrug resistance. Clin. Cancer Res. 18: 1863-1869.
http://dx.doi.org/10.1158/1078-0432.CCR-11-1590
PMid:22344233 PMCid:3359695
El-Osta A, Kantharidis P, Zalcberg JR and Wolffe AP (2002). Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation. Mol. Cell Biol. 22: 1844-1857.
http://dx.doi.org/10.1128/MCB.22.6.1844-1857.2002
PMid:11865062 PMCid:135609
Goldie JH and Coldman AJ (1984). The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res. 44: 3643-3653.
PMid:6744284
Hon GC, Hawkins RD, Caballero OL, Lo C, et al. (2012). Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. Genome Res. 22: 246-258.
http://dx.doi.org/10.1101/gr.125872.111
PMid:22156296 PMCid:3266032
Jin S and Scotto KW (1998). Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol. Cell Biol. 18: 4377-4384.
PMid:9632821 PMCid:109021
Kantharidis P, El-Osta A, deSilva M, Wall DM, et al. (1997). Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance. Clin. Cancer Res. 3: 2025-2032.
PMid:9815593
Kim SN, Kim NH, Lee W, Seo DW, et al. (2009). Histone deacetylase inhibitor induction of P-glycoprotein transcription requires both histone deacetylase 1 dissociation and recruitment of CAAT/enhancer binding protein beta and pCAF to the promoter region. Mol. Cancer Res. 7: 735-744.
http://dx.doi.org/10.1158/1541-7786.MCR-08-0296
PMid:19435809
Kuo MT, Vyas RC, Jiang LX and Hittelman WN (1994). Chromosome breakage at a major fragile site associated with P-glycoprotein gene amplification in multidrug-resistant CHO cells. Mol. Cell Biol. 14: 5202-5211.
PMid:7913517 PMCid:359039
Kusaba H, Nakayama M, Harada T, Nomoto M, et al. (1999). Association of 5' CpG demethylation and altered chromatin structure in the promoter region with transcriptional activation of the multidrug resistance 1 gene in human cancer cells. Eur. J. Biochem. 262: 924-932.
http://dx.doi.org/10.1046/j.1432-1327.1999.00469.x
PMid:10411657
Li LC and Dahiya R (2002). MethPrimer: designing primers for methylation PCRs. Bioinformatics 18: 1427-1431.
http://dx.doi.org/10.1093/bioinformatics/18.11.1427
PMid:12424112
Nakayama M, Wada M, Harada T, Nagayama J, et al. (1998). Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias. Blood 92: 4296-4307.
PMid:9834236
Reed K, Hembruff SL, Sprowl JA and Parissenti AM (2010). The temporal relationship between ABCB1 promoter hypomethylation, ABCB1 expression and acquisition of drug resistance. Pharmacogenomics J. 10: 489-504.
http://dx.doi.org/10.1038/tpj.2010.1
PMid:20125118
Suzuki MM and Bird A (2008). DNA methylation landscapes: provocative insights from epigenomics. Nat. Rev. Genet. 9: 465-476.
http://dx.doi.org/10.1038/nrg2341
PMid:18463664
Toyota M, Kopecky KJ, Toyota MO, Jair KW, et al. (2001). Methylation profiling in acute myeloid leukemia. Blood 97: 2823-2829.
http://dx.doi.org/10.1182/blood.V97.9.2823
PMid:11313277
Ueda K, Pastan I and Gottesman MM (1987). Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene. J. Biol. Chem. 262: 17432-17436.
PMid:2891692
Wise JG (2012). Catalytic transitions in the human MDR1 P-glycoprotein drug binding sites. Biochemistry 51: 5125-5141.
http://dx.doi.org/10.1021/bi300299z
PMid:22647192 PMCid:3383123
Wittwer CT, Reed GH, Gundry CN, Vandersteen JG, et al. (2003). High-resolution genotyping by amplicon melting analysis using LCGreen. Clin. Chem. 49: 853-860.
http://dx.doi.org/10.1373/49.6.853
PMid:12765979
Wojdacz TK and Dobrovic A (2007). Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res. 35: e41.
http://dx.doi.org/10.1093/nar/gkm013
PMid:17289753 PMCid:1874596
Wojdacz TK, Borgbo T and Hansen LL (2009). Primer design versus PCR bias in methylation independent PCR amplifications. Epigenetics 4: 231-234.
PMid:19483476